65,437 trials
Healthy Subjects · Bioavailability · Pharmacokinetics
Primary: Bioequivalence Based on Cmax,ss — 1812.026; 3117.778 ng/mL
Healthy
Primary: Bioequivalence Based on AUC(0-t) — 33883; 32445; 32928; 31841 ng*h/mL
General Anesthesia · Elective Surgery
Primary: Success of Insertion at First Attempt — 50; 60 participants
Major Depressive Disorder · Idiopathic Parkinson Disease
Primary: Number of Participants Reporting Serious Adverse Events or Other Adverse Events Leading Either to Discontinuation or to Death — 13 participants
Asthma
Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05
Healthy
Primary: Bioequivalence Based Cmax — 1230.7; 2947.7 ng/mL
Heart Failure
Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin A1c (HbA1c) — 7.67; 7.61 percentage (%) of total haemoglobin — p=0.606
Influenza, Human
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies — 27.2; 22.8; 33.3; 45.9 titer
Amyloidosis
Primary: Maximum Tolerated Dose — 2 participants with DLT
Breast Cancer
Primary: Pathologic Complete Response (pCR) in the Breast — 4; 38; 3 participants
Severe Chronic Pain
Primary: Patient's Assessment of Pain Severity Score — 7.12; 3.32 Units on a scale
Pain
Primary: Time to Meaningful Pain Relief — 45.4; 63.6 minutes — p=<0.001
Asthma
Primary: The Number of All Randomized Subjects Reporting Adverse Events (AEs). — 109; 103; 56; 50 participants
Overactive Bladder
Primary: Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume — 138; 91; 25; 22 Number of subjects